Phase I, Open Label Study to Examine the Pharmacokinetics, Safety and Tolerability of TMC435 Following Multiple Oral Doses of 100 and 150 mg q.d. in Healthy Chinese Subjects
Phase of Trial: Phase I
Latest Information Update: 06 Oct 2014
At a glance
- Drugs Simeprevir (Primary)
- Indications Hepatitis C
- Focus Pharmacokinetics
- Sponsors Janssen
- 29 Sep 2014 Status changed from recruiting to completed as reported by ClinicalTrials.gov record.
- 16 Jun 2014 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov record.
- 04 Mar 2014 New trial record